Dow Jones Sustainability Indices (DJSI)

Novo Nordisk remained at top of the pharmaceutical sector on the 2017 Dow Jones Sustainability Indices (DJSI) with a score of 80 out of a possible 100. The company’s score is a decrease of three points from 2016, six points behind the 2017 industry leader. Novo Nordisk’s 2017 ranking marks the 18th straight year Novo Nordisk has been a member of the DJSI.

About the DJSI Index

Every year, Novo Nordisk takes part in the extensive Dow Jones Sustainability Index (DJSI) assessment by RobecoSAM, which determines the DJSI ranking. Since 1999, the DJSI has ranked companies’ efforts 

The DJSI is a leading global sustainability benchmark tracking performance of the world's leading companies in terms of economic, environmental and social criteria. The index serves as benchmarks for investors who integrate sustainability considerations into their portfolios, and provides an engagement platform for companies who want to adopt sustainable best practices.

The DJSI is tailored to the asset management industry through its methodology for gathering, analyzing, quantifying, and distributing ESG data. About 3,400 listed companies worldwide take part in the assessment, which covers between 80-120 industry-specific questions focusing on economic, environmental and social factors that are relevant to the companies’ success, but that are under-researched in conventional financial analysis.  

See the DJSI score for Novo Nordisk 2018

See the DJSI score for Novo Nordisk 2017

See the DJSI score for Novo Nordisk 2016

See the DJSI score for Novo Nordisk 2015


Access to Medicine Index

About the Index

Every other year, Novo Nordisk takes part in the extensive Access to Medicine Index (ATMI) ranking. Since 2008, the Access to Medicine Index has ranked pharmaceutical companies’ efforts to improve access to medicine in developing countries. The aim of the Index is to acknowledge and share best practices within the pharmaceutical industry. 

In 2016, Novo Nordisk was ranked tenth in the index; in 2014 we were ranked second; and in 2012 we were ranked sixth.

See the ATMI report card for Novo Nordisk 2016

See the 2016 Access to Medicine Index Overall Ranking

Novo Nordisk report card 2016 - Access to Medicine
Novo Nordisk report card 2016 access to medicine index

Download report card

CDP (Carbon Disclosure Project)

In 2017, we were awarded the performance score ‘A’ on the CDP Climate A list - one of only three pharma companies globally. This is the 15th time we submit information to the CDP report.

About the index

CDP is a not-for-profit organisation that runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impacts.

See the detailed CDP score here

Read Novo Nordisk’s contribution to CDP’s ‘Stories of Change’ report about how companies are taking action on climate change here


CDP Climate A list